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sexually active adolescent and young adult women 
is recommended, only in recent years has there been 
a major emphasis on repeat testing at 3 months 
after diagnosis to identify reinfection.8 Longer than 
recommended testing intervals could miss reinfections 
as these are likely to be of shorter duration than 
primary infections. What were the results of diagnostic 
tests done when pelvic inﬂ ammatory disease was 
diagnosed? Could secular changes in chlamydia test 
technologies or patient management have aﬀ ected 
the size of risk identiﬁ ed in this study? Antigen 
detection methods used during 1995–2000 could 
have missed 50% of infections detectable by second-
generation nucleic acid ampliﬁ cation tests available 
afterwards.9,10 Patients with pelvic inﬂ ammatory 
disease were once routinely admitted to hospital 
and diagnosis of ectopic pregnancy was determined 
surgically, but both transitioned predominantly to 
outpatient management.11 Because ascertainment of 
complications was based solely on hospital records, 
further work is needed to see if cohort members 
attended other primary care settings for milder 
presentations of complications. 
Answers to these questions could help deﬁ ne causes 
of excess risk of reproductive complications seen after 
a positive chlamydia test and inform more eﬀ ective 
interventions leading to improved outcomes. We look 
forward to further mining of this valuable dataset. 
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Equitable control of schistosomiasis and helminthiasis
Over the past decade, the continued high prevalence of 
some neglected tropical diseases (NTDs) has necessitated 
a revision of where and what kind of intensive control 
interventions are needed and what the associated 
targets are.1–4 Set within a global strategy  of preventive 
chemotherapy, as endorsed by WHO, the frontline public 
health method is routine co-administration by mass drug 
administration (MDA), of the anthelmintics praziquantel 
against schistosomiasis and albendazole against soil-
transmitted helminth iasis.5,6 In 2001, an ambitious target 
was set within resolution 54.19 of the World Health 
Assembly to attain regular treatment coverage of at 
least 75% in all school-age children at risk of morbidity. 
With noted progress falling short of this target by 
2010, in January, 2012, several substantial pledges and 
commitments were made at the London Declaration 
on NTDs with an additional World Health Assembly 
resolution 65.21, and both called for intensiﬁ cation of 
eﬀ orts to better rally resources and to ensure an adequate 
provision of medications. 
In The Lancet Infectious Diseases, Nathan Lo and 
colleagues7 show that striving towards 75% coverage 
should now be considered as the minimum standard 
of care in those communities targeted or deemed 
eligible for praziquantel and albendazole treatment. 
They describe novel cost-eﬀ ectiveness analyses of 
current MDA strategies, based on infection prevalence 
thresholds to explore putative outcomes of alternative 
prevalence thresholds as summed over a period of 
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interestingly, they show that, if 21·3% of the population 
shifted to integrated treatment with praziquantel and 
albendazole, programme synergies would lead to a 40% 
reduction in implementation costs (as noted in the 
Article’s appendix). Moreover, their analyses show annual 
preventive chemotherapy against schistosomiasis to 
be highly cost-eﬀ ective in treatment of school-aged 
children at a prevalence of 5% (95% uncertainty interval 
[UI] 1·7–5·2; current guidelines state 50%) and of the 
entire community at 15% (7·3–18·5). Annual MDA 
against soil-transmitted helminthiasis was highly cost-
eﬀ ective in treatment of school-aged children at a 
prevalence of 20% (95% UI 5·4–30·5%; current guidelines 
state 20%) and for the entire community at 60% 
(35·3–85·1). 
Furthermore, Lo and colleagues7 show that earlier 
approaches have not improved equity of access 
to treatment. Nor would these lead to substantial 
disability-adjusted life-years averted.8 By investigation 
of the diﬀ erent scenarios, they surmise that much 
lower prevalence thresholds than WHO norms are 
more sensible. These could be used at international 
and national levels.8,9 However, whether these new 
norms for control eﬀ orts are entirely practical is not 
yet clear, because if their advice was closely followed, 
overestimation of the bottlenecks and strictures 
in logistics that need to be overcome in this new 
logical chain of events is likely. Without doubt, more 
information on best implementation strategies is 
needed to sensibly guide its transition and application 
such that expanded access is not counterproductive. 
Foremost, dramatic change is needed in our appraisal 
of these diseases by reducing existing barriers to 
expansion of treatment, irrespective of age, sex, and 
disability.
Using their analytical framework, Lo and colleagues7 
estimate that treatment needs for Africa are six 
times higher than current guidelines for praziquantel 
and two times higher for albendazole. Thus, the 
consequences for country programming are immense; 
the MDA strategies might prove to be cost-eﬀ ective, 
but the involved total budgets and other investments 
needed will be substantial in absolute terms for each 
country involved. Implementation of the suggested 
framework is a major undertaking, in view of the 
paucity of resources in other priority areas within 
NTD programmes and other health domains. From a 
budgetary perspective, a realistic limited budget might 
actually facilitate up-scaled, stepwise implementation 
and prevent rejection as unrealistic in real life. In 
their analyses, Lo and colleagues used county-speciﬁ c 
aﬀ ordability standards related to their available national 
income. In all scenarios,1,10 increased drug subsidies11–13 
and donations from pharmaceutical companies, strong 
political will, increased logistical support, and improved 
epidemiological surveillance to monitor for drug 
resistance are needed. At lower prevalence levels, the 
at-risk vulnerable populations14 may be living in poverty 
and be harder to reach11 and lower compliance will 
lead to lower returns. Additionally, Lo and colleagues7 
note the extra eﬀ ort and resources needed nationally 
to improve the quality of the existing expanded MDA 
programmes. 
Although Lo and colleagues7 reason that treatment 
expansion is both ﬁ nancially and geographically 
appealing, extension of coverage is also soundly justiﬁ ed 
ethically.11 A key feature will be securing additional 
pledges from the pharmaceutical sector to provide 
stocks to ensure continuous drug delivery pipelines. 
Similarly, we need to put in place strategies to ensure 
that treatment fatigue among those receiving MDA 
treatment over many years within the community does 
not dampen the recipients’ compliance and that their 
demand for treatment continues to match the available 
and future supply through national services and donors. 
In revising preventive chemotherapy guidelines, 
broader quantitative and qualitative evidence should 
also be incorporated and collected to optimise the 
implementation of treatment campaigns, which 
often have low uptake. Although these interventions 
are potentially cost-eﬀ ective, they might not be all 
aﬀ ordable within countries’ tight budgets. At least, 
they are a next, essential step in the promotion of 
universal access for the prevention and treatment of 
NTDs as also envisaged in WHO’s Expended Project for 
the Elimination of NTDs (ESPEN) and the Sustainable 
Development Goals. 
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Global maternal group B streptococcus colonisation 
Globally, neonatal mortality remains unacceptably 
high, with little change in the death rate since 1990, 
despite a halving of under-5 mortality in the same 
timeframe.1 Group B streptococcus is the leading 
cause of neonatal mortality in the UK2 and the 
USA,3 with long-term adverse neurodevelopmental 
outcomes in up to 50% of survivors.4 In low-income 
and middle-income countries, little is known about 
the role of group B streptococcus in neonatal deaths.5 
Disease estimates in these countries might be an 
underestimation of the true disease burden because 
the need for selective growth media to identify group 
B streptococcus has been under-recognised.5,6
Group B streptococcus acquisition occurs through 
vertical transmission in 15–50% of infants born to a 
group B streptococcus colonised mother.7 Maternal 
colonisation is a prerequisite for early-onset and a risk 
factor for late-onset disease.3 Intrapartum antibiotics 
can prevent early-onset group B streptococcal disease, 
and, as a consequence, in many high-income countries 
this form of the disease has become much less common.3 
Apart from the dangers of widespread antibiotic use, 
intrapartum antibiotics pose logistical and ﬁ nancial 
problems in low-income and middle-income settings 
and are poorly implemented.8,9 An eﬀ ective and cost-
eﬃ  cient alternative to intrapartum antibiotics is to 
implement a maternal vaccination strategy. However, 
because estimates of disease burden and disease-causing 
serotypes are only available in a few countries, the 
development of a global vaccine has proven problematic. 
To estimate the true burden of group B streptococcal 
disease, measurement of maternal colonisation by 
country might be useful, because maternal colonisation is 
the main risk factor for early-onset group B streptococcal 
disease. In a previous systematic review, Stoll and 
colleagues10 showed that, by contrast with group B 
strepto coccus invasive disease prevalence, maternal 
group B streptococcus colonisation rates in low-income 
and middle-income settings were similar to those of 
high-income countries. However, laboratory methods 
precluded extrapolation of the data to provide a global 
estimate. Therefore, if diﬀ erences in disease rates are 
solely a result of a combination of intrapartum antibiotics 
and laboratory methods, then using standardised 
laboratory methods should show a variation in maternal 
colonisation in line with disease estimates. 
In The Lancet Infectious Diseases, Gaurav Kwatra 
and colleagues11 identiﬁ ed prospective studies that 
used standardised laboratory methods for group B 
streptococcus identiﬁ cation to calculate a robust 
estimate of the true burden of maternal colonisation. 
Their ﬁ ndings from 73 791 pregnant women in 
78 studies across 37 countries showed an overall global 
estimate of 17·9% (95% CI 16·2–19·7). Their results 
highlight substantial variation between and within 
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